Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368257 | 0.74 | GPR84 (0.42) | GPR84HTR2CSLC6A4HTR2BMAOB | |
| SCHEMBL693167 | 0.74 | MAOB (0.41) | GPR84HTR2CSLC6A4HTR2BMAOB | |
| SCHEMBL31098255 | 0.72 | IDO1 (0.40) | APPMEN1KMT2AIDO1 | |
| SCHEMBL21878476 | 0.72 | IDO1 (0.40) | APPMEN1KMT2AIDO1 | |
| SCHEMBL20360817 | 0.72 | ELOVL1 (0.49) | HTR2CSLC6A4HTR2BTAAR1ELOVL1 | |
| SCHEMBL20173484 | 0.72 | KDM4E (0.42) | TAAR1 | |
| SCHEMBL4591760 | 0.72 | NPC1 (0.39) | MEN1KMT2AMCHR1 | |
| SCHEMBL2997865 | 0.71 | APP (0.51) | APPMAOBMEN1KMT2AIDO1 | |
| SCHEMBL11181089 | 0.71 | TAAR1 (0.44) | GPR84HTR2CSLC6A4HTR2BMAOB | |
| SCHEMBL30354806 | 0.71 | TAAR1 (0.44) | GPR84HTR2CSLC6A4HTR2BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560654-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| EP-2421368-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | CFTR, PKD1, PKD2 | APP 2674/4885GPR84 558/4885HTR2C 1157/4885 |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | SCN1A, CLIC1, CLCN2 | APP 1371/4885GPR84 3493/4885HTR2C 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.